 Phase II trial piritrexim metastatic melanoma intermittent low-dose administration phase II trial piritrexim pyrido- pyrimidine PTX patients metastatic malignant melanoma intermittent low-dose oral administration schedule PTX dose mg times day days weeks week rest patients study patients assessable response complete responses CRs partial responses PRs response rate CR PR confidence limit responses soft tissue lesions responses lung lesions initial dose schedule dose-limiting toxicity myelosuppression PTX schedule active malignant melanoma Further clinical trials results underway